KMCRIC

In human research, THC and CBD had opposing effects on psychosis. In healthy human volunteers, anxiety and psychotic-like symptoms were observed to occur with THC; however, these effects were significantly reduced by CBD [​43​;​44​;​45​]. Neuroimaging [​46​] and animal research [​47​] have reported similar findings for CBD. According to a systematic review, use of standard pharmacotherapy for mental illness is effective for reducing cannabis use by people with depression or psychotic disorders [​48​]. According to a review of treatment of patients with both psychiatric disorders and evidence of substance abuse, there is some evidence to suggest the benefit of psychiatric medications for the substance abuse; however, evidence of efficacy is limited for antidepressants, and second-generation antipsychotics (clozapine, olanzapine, and risperidone) may be more effective [​49​]. A study cited in a systematic review suggested that the antipsychotic effects of neuroleptics were reported to be antagonized by cannabinoids [​50​].

... 정신 약물의 이점을 제시하는 몇 가지 근거가 있다; 그러나, 효능의 근거는 항우울제에 제한되며, 제 2세대 정신과 약물 (클로자핀, 올란자핀, 리스페리돈)은 더 효과적 일 수 있다 [​49​]. 체계적인 고찰에 인용된 연구는...

In available clinical research, benefit from cannabis-based therapies for cancer-related anorexia-cachexia syndrome was lacking [​54​]; however, early research suggests a benefit of dronabinol on weight gain in patients with cystic fibrosis [​55​] and on appetite and weight in patients with AIDS [​56​]. In patients with eating disorders, THC had a lack of effect on weight, caloric intake, and psychiatric assessment [​57​].

... 섬유증 환자의 체중 증가 [​55​] 및 후천성 면역 결핍증 환자의 식욕과 체중에 [​56​] 대한 드로나비놀의 이점을 제시한다. 섭식 장애 환자에게서, 체중, 칼로리 섭취량, 및 정신과 평가에 대한 THC의 효과는 부족했다 [​57​]....